US FDA authorises BioCryst's IV peramivir for emergency H1N1 use – updated
This article was originally published in Scrip
Executive Summary
The US FDA has authorised BioCryst Pharmaceuticals' antiviral IV peramivir for emergency use in hospitalised H1N1 patients. BioCryst shares were up 11% on Nasdaq in pre-market trading on October 26th on the news.